A particular concern has been mentioned by a respondent with regard to the Danish market for oilseed rape graminicides where the parties' market share exceeds [50 to 60]* % with the products Fusilade from AstraZeneca ([20 to 30]* %) and Agil from Novartis ([30 to 40]* %), the only other registered product being Dow's Gallant (based on haloxyfob).
Se on meistä kiinni nyt.Mitä sitten, jos emme pysty pysäyttämään sitä?EurLex-2 EurLex-2